EMERYVILLE, Calif., Sept. 21, 2011 (GLOBE NEWSWIRE) — NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide(R) compounds for the local non-systemic treatment and …
